SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 19, 2002; DOI 10.1182/blood-2002-07-1969. This Article Full Text (PDF) All Versions of this Article: 2002-07-1969v1 101/3/849    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Virts, E. L Articles by Raschke, W. C Search for Related Content PubMed PubMed Citation Articles by Virts, E. L Articles by Raschke, W. C Social Bookmarking                   What's this? Submitted July 3, 2002 Accepted September 9, 2002 A CD45 minigene restores regulated isoform expression and immune function in CD45-deficient mice: therapeutic implications for human CD45-null severe combined immunodeficiency Elizabeth L Virts, Oscar Diago, and William C Raschke* Sidney Kimmel Cancer Center, San Diego, CA, USA * Corresponding author; email: braschke{at}skcc.org. Transgenic mice have been generated which carry a CD45 minigene under control of the human leukocyte function-associated antigen (LFA-1, CD11a) promoter. CD45-null mice carrying the transgene exhibit the lymphocyte lineage-specific isoform expression patterns of wild type mice. Furthermore, these mice have normal thymocyte development and peripheral T cell numbers. The proliferative ability of T cells in response to mitogens and antigen also is regained, as is B cell responsiveness to anti-IgM. The antibody response to antigen is also restored and is similar to that of normal mice. Therefore, introduction of a functional CD45 minigene is sufficient to overcome the principal SCID-associated defects and represents a potential route to a gene therapy for human CD45-deficent SCID. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. G. Panchal, R. L. Ulrich, S. B. Bradfute, D. Lane, G. Ruthel, T. A. Kenny, P. L. Iversen, A. O. Anderson, R. Gussio, W. C. Raschke, et al. Reduced Expression of CD45 Protein-tyrosine Phosphatase Provides Protection against Anthrax Pathogenesis J. Biol. Chem., May 8, 2009; 284(19): 12874 - 12885. [Abstract] [Full Text] [PDF] B. E. Collins, O. Blixt, A. R. DeSieno, N. Bovin, J. D. Marth, and J. C. Paulson Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact PNAS, April 20, 2004; 101(16): 6104 - 6109. [Abstract] [Full Text] [PDF] S. Ogilvy, C. Louis-Dit-Sully, J. Cooper, R. L. Cassady, D. R. Alexander, and N. Holmes Either of the CD45RB and CD45RO Isoforms Are Effective in Restoring T Cell, But Not B Cell, Development and Function in CD45-Null Mice J. Immunol., August 15, 2003; 171(4): 1792 - 1800. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020